Level C· Early human research exploring benefitsCase Report / SeriesPubMedOpen access

Microvesicles isolated from 5-azacytidine-and-resveratrol-treated mesenchymal stem cells for the treatment of suspensory ligament injury in horse-a case report.

Kornicka-Garbowska K., Pędziwiatr R., Woźniak P., Kucharczyk K., Marycz K.

Case Report / Series on Ligament Injury, Chronic Wound, published in Stem Cell Res Ther (2019) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Case Report / Series
Journal
Stem Cell Res Ther (2019)
Country
England
Reported sample size
—
Source database
PubMed
PMID
31852535
PMCID
PMC6921487
DOI
10.1186/s13287-019-1469-5
Citations
21

Abstract (original English)

Background In athlete horses, suspensory ligament (SL) injuries are the most common cause of lameness. Healing of SL injury is still problematic, and even proper rehabilitation and pharmacological therapy do not guarantee returning to the initial performance level. In our previous studies, we have shown that a combination of 5-azacytidine (AZA) and resveratrol (RES) exerts beneficial, rejuvenating effects on metabolic syndrome derived adipose-derived stem cells (ASCs). Thus, in the presented research, we investigate whether not only rejuvenated ASC but also microvesicles (MVs AZA/RES ) secreted by them possess enhanced regenerative properties in SL injury. Methods In the presented study, a 6-year-old Dutch Warmblood gelding, working in jumping, was diagnosed with SL injury using ultrasonography, Doppler, real-time elastography and thermography. As a therapeutic strategy, the affected animal was treated with extracellular microvesicles derived from ASC treated with the combination of 5-azacytydine (AZA) and resveratrol (RES) (MVs AZA/RES ) . RESULTS: First, anti-apoptotic effects of MVs AZA/RES were tested in co-culture with metabolic syndrome derived ASC. The proliferation of cells and expression of pro-apoptotic genes were investigated. Then, MVs AZA/RES were injected directly into the injured SL of the Dutch Warmblood gelding. In vitro assays revealed that MVs AZA/RES enhance

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsAzacitidineCell-Derived MicroparticlesElasticity Imaging TechniquesHorse DiseasesHorsesLigamentsMesenchymal Stem CellsResveratrolUltrasonography

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research